Fulcrum discontinues sickle cell drug after FDA concerns

Key facts

• Fulcrum is discontinuing its sickle cell drug.
• The FDA raised concerns about the drug's efficacy and safety.
• The U.S. Food and Drug Administration expressed reservations about the drug.

The FDA's decision to express concerns about a drug's efficacy and safety can significantly impact a pharmaceutical company's development pipeline and market prospects. Such reservations often lead to discontinuation of the drug, affecting investor confidence and future research funding.